Servier’s Post

Think outside the box

💡In IQVIA Institute’s Rethinking Clinical Trial Country Prioritization report, researchers highlight country trial readiness by using an algorithm that integrated country infrastructure, clinical capabilities and patient availability metrics. The researchers discovered that ranking the countries based on the Operating Infrastructure metrics, the Clinical Infrastructure metrics and the Patient Availability metrics leads to significantly different ordering. For example, India and Brazil rank high for patient availability but fall in the bottom quartile for clinical infrastructure. This highlights a crucial challenge in balancing clinical trial readiness and opportunity. Read about these findings and more by downloading the report ➡️ https://bit.ly/4cm2scv #GlobalHealth #HealthEquity #ClinicalTrials

Cracking the EMA Code: Week 2 - Expert Insights on Clinical Trials for Rare Diseases Unlock the secrets to successful rare disease clinical trials in Europe with the latest release in our 7-part series, article 3! Professor Boris Kramer, MD, PhD, a renowned expert in neonatology and translational science, shares his extensive experience in designing and executing effective trials. Discover: 💚The collaborative approach to clinical trial design that ensures patient-centricity and regulatory compliance. 💚Strategies for selecting meaningful endpoints that resonate with regulatory authorities and payers. 💚Key considerations for navigating the unique challenges of rare disease trials. This is not one to miss! Head to our website to read the full article: https://lnkd.in/e2PZnDJ9 Don't miss the opportunity to discuss your clinical trial strategy with a leading expert. Contact Partner Rare today to schedule a free consultation with Professor Boris Kramer. https://lnkd.in/gRJHVmnZ #raredisease #clinicaltrials #drugdevelopment #EMA #EUPharma #patientadvocacy #healthequity #biotech

Article 3 in our 7-Part Series, 'Cracking the EMA Code' is now live over at Partner Rare. Professor Boris Kramer, MD. PhD shares his extensive experience in designing and conducting clinical trials with a focus on rare disorders. Discover: 💚 The collaborative approach to clinical trial design that ensures patient-centricity and regulatory compliance. 💚Strategies for selecting meaningful endpoints that resonate with regulatory authorities and payers. 💚Key considerations for navigating the unique challenges of rare disease trials. This is not one to miss! If you're approaching your planning phase for a clinical trial and would like to discuss your requirements with Professor Kramer, get in touch and we'll arrange for you and your team to have a complimentary discussion with our team of rare disease experts. #raredisease #clinicaltrials #drugdevelopment #EMA #EUPharma #patientadvocacy #biotech #USbiotech

Today is International Clinical Trials Day. It’s an important day to recognise and reflect on all that has been accomplished thanks to clinical trials and the people behind them. Gilead ANZ plays an important role supporting clinical trials, engaging with some of the world’s best researchers working across a strong local clinical trial ecosystem. Today we also acknowledge and thank the patients, as without them clinical trials would not be possible. Your efforts drive progress and hope for a healthier future. #ClinicalTrialsDay #InternationalClinicalTrialsDay

Celebrating Innovation and Dedication on Clinical Trials Day 2024 🎉 Today, we honour the incredible contributions of clinical researchers and participants around the world on Clinical Trials Day. Their unwavering commitment to advancing medicine has played a pivotal role in enhancing healthcare for us all ❗ Clinical trials are the backbone of medical progress, providing us with valuable insights and leading to breakthroughs that save lives. The journey from the laboratory 🔬 to the patient’s bedside 🛏 is long and complex, but it’s through the dedication of countless individuals that we can turn possibilities into realities. Here are some impactful statistics that highlight the significance of clinical trials: ✔ The Association of Clinical Research Professionals (ACRP) has more than 16,500 members globally, representing a diverse and dedicated workforce. ✔ Clinical Trials Day is a tradition since 2014, celebrating the achievements and progress made through clinical research. ✔ The 2024 theme, “Trailblazers Among Us,” emphasizes the relentless pursuit of knowledge and the exacting application of best practices by clinical research professionals. Let’s take a moment to appreciate the hard work, innovation, and collaboration that go into every study. It’s through these efforts that we can look forward to a healthier future for everyone. 🙏 Thank you to all the researchers, healthcare professionals, and trial participants who make this possible. Your work does not go unnoticed, and the impact of your contributions will be felt for generations to come. #WeAreIQVIA #ClinicalTrialsDay #cFSPCares #SMSupports #HealthcareHeroes If you'd like to explore more about clinical trial conducted at IQVIA click on the link!

Today, the U.S. FDA issued a draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” to assist medical product sponsors in submitting Diversity Action Plans to support certain clinical studies. Diversity Action Plans are intended to increase clinical study enrollment of participants of historically underrepresented populations to help improve the data the agency receives about the patients who may potentially use the medical product. Enhancing diversity within clinical studies not only facilitates broader applicability of results across a broad spectrum of patient populations, but also enhances understanding of the disease or medical product under study, thus providing valuable insights to inform the safe and effective use of the medical product among patients. #genomics #clinicaltrialdiversity #fda Draft Guidance: https://lnkd.in/eHUw3hVS

Discover strategies to boost enrollment at clinical research sites in our latest blog. Get actionable tips to address common challenges and ensure successful clinical trials. » https://bit.ly/3ZMrle2 #clinicalresearch #nonenrollingsites #researchsites

Protas and Duke Clinical Research Institute (DCRI) formed a strategic collaboration in May 2023 to transform clinical research by radically changing the way trials are designed and delivered. Discover a new article, co-written by Prof Sir Martin Landray, DCRI, Duke-Margolis Institute for Health Policy and Clinical Trials Transformation Initiative (CTTI), exploring opportunities to improve evidence generation in US-based clinical trials:  https://lnkd.in/e4UPSAbm The article discusses how to create a new infrastructure that brings trials closer to the diverse populations they serve. #clinicaltrials #clinicalresearch #diversity  

Celebrate #ClinicalTrialsDay today by checking out the newly released Toward a National Action Plan for Achieving Diversity in Clinical Trial, which includes eight domains and action steps intended to drive system-wide collective action. The need to improve diversity in clinical trials has been evident for many years, but a multi-sector action plan for system-wide, sustainable change was lacking. This foundational document is a call to collective action that has been (and continues to be) informed by the shared wisdom of hundreds of leaders in health equity and representation involved in a series of convenings over the last year. These include meetings held by the Clinical Trials Transformation Initiative (CTTI) in June 2023, the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) in September 2023, Milken Institute’s FasterCures in November 2023, and the meeting today May 20, 2024, hosted by the National Academies Forum on Drug Discovery, Development, and Translation. We call on each of us from across the clinical research enterprise to step forward and commit to working together to implement this National Action Plan and achieve representative clinical trials. https://lnkd.in/eYa3nNYW